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Introduction

Methods

Acute myocardial infarction (MI) is a major cause of morbidity and
mortality worldwide. The goal of therapy is to limit the irreversible cell
damage via quick reperfusion. However, the restoration of blood flow
to a prolonged ischemic area (MI/R) per se can induce additional
cardiac damage [1]. Currently, there are no effective treatments to
mitigate this reperfusion induced injury. Oxidative stress,
characterized as the rapid production of reactive oxygen species, has
been indicated to mediate MI/R injury. Mitochondria may be a principle
source of oxidative stress causing MI/R injury. Coenzyme Q10
(CoQ10) is essential for electron transport chain (ETC) in normal
mitochondria. It accepts the electron generated from complex I or II to
form its reduced form, ubiquinol; then donates the electron to complex
III to return its oxidized form, ubiquinone (see figure 1). The
bioavailability of CoQ10 is likely reduced during MI/R, which can
interrupt the electron transport via ETC, and then free electrons may
bind to oxygen to generate superoxide during early reperfusion and
attribute to the oxidative stress [2]. CoQ10 also has antioxidant
properties and has been used as an adjunctive agent in the treatment
of cardiovascular disease, such as congestive heart failure and
hypertension [3]. Coenzyme Q1 (CoQ1) is a derivative of CoQ10, but
is a more potent antioxidant than CoQ10 due to a shorter isoprene
chain (see figure 2) [4]. This study tested the effects of CoQ10 and
CoQ1 on postreperfused cardiac function and infarct size in an
isolated rat MI/R model.

Isolated Rat Heart MI/R Experiments: Langendorff heart preparation
was performed after anesthesia of male Sprague Dawley rats (275-325
g, Charles River, Springfield MA). Hearts were isolated and
retrogradely perfused with Krebs’ buffer at a constant pressure of 80
mmHg with 37°C and pH of 7.35-7.45 by aerating with 95% O2/5%
CO2 to get the baseline of cardiac parameters. After 15 min of baseline
perfusion, the heart was put through global ischemia by stopping
perfusion for 30 min, followed by reperfusion for 45 min. Krebs’ buffer
alone, 0.2% DMSO alone (0.2% DMSO was used to solubilize CoQ1
and CoQ10), CoQ1 (20 µM), or CoQ10 (20 µM) was infused with 1
ml/min for the first 5 min of reperfusion. The pressure transducer
(SPR-524, Millar Instruments, Inc., Houston, TX) was inserted into the
left ventricle to record left ventricular end systolic pressure (LVESP),
left ventricular end diastolic pressure (LVEDP), maximal rate of left
ventricular systolic pressure over time (dP/dtmax), minimal rate of left
ventricular diastolic pressure over time (dP/dtmin) and heart rate.
Coronary flow was measured by a flow probe which was placed in line
with perfusion line. Data was recorded using a Powerlab Station
acquisition system (ADInstruments, Grand Junction, CO) every 5 min
during the baseline and reperfusion.
Determination of Infarct size: At the end of the experiments, the left
ventricle of the hearts were sectioned into 2 mm thick slices that were
subjected to 1% triphenyltetrazolium chloride (TTC) staining to detect
infarcted (unstained) and viable (stained brick red) area. Infarct size
was expressed as the percentage of infarcted tissue weight to the total
tissue weight.
Statistical Analysis: All data in the figures are presented as means ±
S.E.M. The data was analyzed by analysis of variance using post hoc
analysis with Fisher’s PLSD test. p<0.05 are considered to be
statistically significant.

Results

Figure 4. Time course of dP/dtmax for Sham, MI/R, MI/R+ DMSO, MI/R + 20 µM CoQ1, MI/R
+ 20 µM CoQ10 groups. Control MI/R and MI/R + DMSO exhibited significantly lower postreperfused dP/dtmax compared to the Sham. By contrast, application of 20 µM CoQ1
significantly improved post-reperfused dP/dtmax, which was significantly higher compared to
the untreated MI/R controls and the effects of 20 µM CoQ10 treatment. (* p< 0.05, ** p< 0.01
vs. MI/R and MI/R + DMSO; # p< 0.05 vs. MI/R + 20 µM CoQ10)
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Figure 5. The representative TTC
staining pictures and summarized
infarct size graph for experimental
groups. Sham, CoQ1, and CoQ10
groups exhibited significantly lower
infarct size compared to the MI/R
group. (** p< 0.01 vs. MI/R)

Conclusions
Figure 1. The role of CoQ10 in electron transport chain in mitochondria. CoQ10 will
transport electron between the conversion of its oxidized form (e.g., ubiquinone) and reduced
form (e.g., ubiquinol). (adapted from 2012 Pearson education, Inc).

Our results indicate that CoQ1 was more effective than CoQ10 in
restoring post-reperfused cardiac contractile function, but not infarct
size during MI/R. These differences may be attributed to CoQ1’s
stronger antioxidant effects.
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Figure 2. The chemical structure of
CoQ10 and CoQ1. CoQ10 has the
1,4-benzoquinone chemical group
with 10 isoprenyl subunits in its tail.
By contrast, CoQ1 only has 1
isoprenyl subunit in its tail.

Hypothesis
We hypothesized that CoQ10 and CoQ1 would improve postreperfused cardiac contractile function and reduce infarct size when
compared to I/R control with/without drug solvent.

Figure 3. Time course of LVDP for Sham, MI/R, MI/R+ DMSO, MI/R + 20 µM CoQ1, MI/R +
20 µM CoQ10 groups. LVDP is the difference between LVESP and LVEDP. Control MI/R and
MI/R + DMSO exhibited significantly lower post-reperfused LVDP compared to the Sham. By
contrast, application of 20 µM CoQ1 significantly improved post-reperfused LVDP, which was
significantly higher compared to the untreated MI/R controls and the effects of 20 µM CoQ10
treatment. (* p< 0.05, ** p< 0.01 vs. MI/R and MI/R + DMSO; # p< 0.05 vs. MI/R + 20 µM
CoQ10)
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